Alpha-GPC | Glycerophosphocholine | Choline alphoscerate | L-alpha-glycerophosphocholine
Supports cognitive function*
Supports exercise performance*
Alpha-glycerophosphocholine (alpha-GPC) is a choline-containing phospholipid that can be used to augment the body and brain choline pool. In this role it serves as a precursor for both acetylcholine and phosphatidylcholine biosynthesis. Alpha-GPC and citicoline (i.e., CDP-choline) are considered the nootropic forms of choline, with both forms able to increase brain choline levels, act as building blocks for acetylcholine, and support choline-dependent neurotransmission.[1–4]* However, of the two, alpha-GPC contains a higher proportion of choline, so a lower dose of alpha-GPC gives greater choline support than a similar dose of citicoline.[5–7] This means that by weight alpha-GPC is the more efficient choline precursor. Following an oral dose, alpha-GPC metabolizes into choline and the phospholipid glycerophosphate. The choline can be used for acetylcholine synthesis and neurotransmission.[3,8–14] Acetylcholine is central to brain neurotransmission; it’s also used in both the fight or flight and rest and relax parts of the autonomic nervous system; and it is a signaling molecule for activating muscles. Because alpha-GPC is a precursor in the biosynthesis of acetylcholine, it plays a supportive role in a variety of cognitive functions, including attention, concentration, mental focus, and memory formation and recall.* Alpha-GPC also supports aspects of muscle performance, and is involved in maintaining organs and tissues.* And, because alpha-GPC can be readily metabolized into phosphatidylcholine, it can be used to support the structure and function of cell membranes. Alpha-GPC is found in low amounts in a variety of foods and in breast milk.[17,18]
Alpha-glycerophosphocholine (Alpha-GPC) is a source of choline; it is able to influence both systemic and brain concentrations of choline.
Alpha-GPC is derived from soy.
Neurohacker uses an Alpha-GPC that is sourced to be non-GMO, gluten-free, and vegan.
Alpha-glycerophosphocholine (Alpha-GPC) is by weight one of the best sources of choline. While alpha-GPC is often treated as if it’s dose-dependent (i.e., a higher dose is better) and doses of 1200 mg/day have been used in some clinical studies, Neurohacker believes the evidence suggests a threshold response (see Neurohacker Dosing Principles) when alpha-GPC is given to healthy people. This means that more might not be better under all circumstances. As an example, in a study of healthy college-aged men, while the higher dose (500 mg/day) of alpha-GPC did a better job increasing free choline levels, the lower dose (250 mg/day) produced a better peak muscle force response. In general, Neurohacker’s experience with alpha-GPC (as well as citicoline) indicate that when used as part of comprehensive nootropic formulations, a more modest dose is often sufficient. Alpha-GPC is a useful choline source in liquids because of its taste and solubility. In general, the best time to take alpha-GPC is early in the day.
Augments choline pool
Alpha-GPC is part of the CDP-choline (or Kennedy) pathway, which has a central role in choline homeostasis [13,14]
Supports plasma choline levels 
Precursor for phosphatidylcholine synthesis 
Precursor for acetylcholine synthesis [2,3]
Supports memory and learning [7,27,36]
Supports attention [7,36]
Supports cognition [2,3,15,36,37]
Supports acetylcholine synthesis and release [2,3,21]
Supports vesicular acetylcholine transporter levels [21,22]
Supports high affinity choline uptake transporter levels 
Protects from age-related changes in cholinergic neurotransmission 
Supports dopamine synthesis and release [1,24]
Supports dopamine plasma membrane transporter (DAT) levels 
Supports serotonin synthesis 
Supports GABA release 
Supports phospholipid synthesis [9,26]
Supports phosphoinositide synthesis [26,27]
Supports protein kinase C (PKC) activation [28–30]
Supports growth hormone secretion from the pituitary gland [10,20,31]
Counters some age-related brain microstructural changes [32–35]
Supports neuroprotective functions [2,3]
Supports isometric force production 
Supports maximum power and velocity in jump movements 
CDP-choline, Uridine Monophosphate, Huperzine A, Bacopa monnieri, Celastrus paniculatus, Coleus forskohlii, Vitamin B5 in supporting cholinergic neurotransmission
M. Trabucchi, S. Govoni, F. Battaini, Farmaco Sci. 41 (1986) 325–334.
C.M. Lopez, S. Govoni, F. Battaini, S. Bergamaschi, A. Longoni, C. Giaroni, M. Trabucchi, Pharmacol. Biochem. Behav. 39 (1991) 835–840.
S. Sigala, A. Imperato, P. Rizzonelli, P. Casolini, C. Missale, P. Spano, Eur. J. Pharmacol. 211 (1992) 351–358.
N. Canal, Others, Le Basi Raz Ter 23 (1993) 102.
R. Di Perri, G. Coppola, L.A. Ambrosio, A. Grasso, F.M. Puca, M. Rizzo, J. Int. Med. Res. 19 (1991) 330–341.
G. Gatti, N. Barzaghi, G. Acuto, G. Abbiati, T. Fossati, E. Perucca, Int. J. Clin. Pharmacol. Ther. Toxicol. 30 (1992) 331–335.
L. Parnetti, F. Mignini, D. Tomassoni, E. Traini, F. Amenta, J. Neurol. Sci. 257 (2007) 264–269.
I.H. Ulus, R.J. Wurtman, C. Mauron, J.K. Blusztajn, Brain Res. 484 (1989) 217–227.
G. Abbiati, T. Fossati, G. Lachmann, M. Bergamaschi, C. Castiglioni, Eur. J. Drug Metab. Pharmacokinet. 18 (1993) 173–180.
G.P. Ceda, G.P. Marzani, V. Tontodonati, E. Piovani, A. Banchini, M.T. Baffoni, G. Valenti, A.R. Hoffman, in: Growth Hormone II, Springer New York, 1994, pp. 328–337.
J.P. Fernández-Murray, C.R. McMaster, J. Biol. Chem. 280 (2005) 38290–38296.
F. Amenta, S.K. Tayebati, D. Vitali, M.A. Di Tullio, Mech. Ageing Dev. 127 (2006) 173–179.
Z. Li, D.E. Vance, J. Lipid Res. 49 (2008) 1187–1194.
F. Gibellini, T.K. Smith, IUBMB Life 62 (2010) 414–428.
N. Canal, M. Franceschi, M. Alberoni, C. Castiglioni, P. De Moliner, A. Longoni, Int. J. Clin. Pharmacol. Ther. Toxicol. 29 (1991) 103–107.
S.H. Zeisel, M.-H. Mar, J.C. Howe, J.M. Holden, The Journal of Nutrition 133 (2003) 1302–1307.
M.Q. Holmes-McNary, W.L. Cheng, M.H. Mar, S. Fussell, S.H. Zeisel, Am. J. Clin. Nutr. 64 (1996) 572–576.
Y.O. Ilcol, R. Ozbek, E. Hamurtekin, I.H. Ulus, J. Nutr. Biochem. 16 (2005) 489–499.
L. Marcus, J. Soileau, L.W. Judge, D. Bellar, J. Int. Soc. Sports Nutr. 14 (2017) 39.
T. Kawamura, T. Okubo, K. Sato, S. Fujita, K. Goto, T. Hamaoka, M. Iemitsu, Nutrition 28 (2012) 1122–1126.
S.K. Tayebati, D. Tomassoni, A. Di Stefano, P. Sozio, L.S. Cerasa, F. Amenta, J. Neurol. Sci. 302 (2011) 49–57.
D. Tomassoni, A. Catalani, C. Cinque, M.A. Di Tullio, S.K. Tayebati, A. Cadoni, I.E. Nwankwo, E. Traini, F. Amenta, Curr. Alzheimer Res. 9 (2012) 120–127.
F. Amenta, F. Franch, A. Ricci, J.A. Vega, Ann. N. Y. Acad. Sci. 695 (1993) 311–313.
S.K. Tayebati, D. Tomassoni, I.E. Nwankwo, A. Di Stefano, P. Sozio, L.S. Cerasa, F. Amenta, CNS & Neurological Disorders - Drug Targets 12 (2013) 94–103.
L. Ferraro, S. Tanganelli, L. Marani, C. Bianchi, L. Beani, A. Siniscalchi, Neurochem. Res. 21 (1996) 547–552.
G. Aleppo, F. Nicoletti, M.A. Sortino, G. Casabona, U. Scapagnini, P.L. Canonico, Pharmacol. Toxicol. 74 (1994) 95–100.
G. Schettini, C. Ventra, T. Florio, M. Grimaldi, O. Meucci, A. Scorziello, A. Postiglione, A. Marino, Pharmacol. Biochem. Behav. 43 (1992) 139–151.
S. Govoni, F. Battaini, L. Lucchi, A. Pascale, M. Trabucchi, Ann. N. Y. Acad. Sci. 695 (1993) 307–310.
L. Lucchi, A. Pascale, F. Battaini, S. Govoni, M. Trabucchi, Life Sci. 53 (1993) 1821–1832.
S. Govoni, L. Lucchi, F. Battaini, M. Trabucchi, Life Sci. 50 (1992) PL125–8.
G.P. Ceda, G. Ceresini, L. Denti, G. Marzani, E. Piovani, A. Banchini, E. Tarditi, G. Valenti, Horm. Metab. Res. 24 (1992) 119–121.
F. Amenta, M. Del Valle, J.A. Vega, D. Zaccheo, Mech. Ageing Dev. 61 (1991) 173–186.
A. Ricci, E. Bronzetti, J.A. Vega, F. Amenta, Mech. Ageing Dev. 66 (1992) 81–91.
F. Amenta, F. Ferrante, J.A. Vega, D. Zaccheo, Prog. Neuropsychopharmacol. Biol. Psychiatry 18 (1994) 915–924.
G. Muccioli, G.M. Raso, C. Ghé, R. Di Carlo, Prog. Neuropsychopharmacol. Biol. Psychiatry 20 (1996) 323–339.
L. Parnetti, F. Amenta, V. Gallai, Mech. Ageing Dev. 122 (2001) 2041–2055.
F. Amenta, A. Carotenuto, A.M. Fasanaro, R. Rea, E. Traini, J. Neurol. Sci. 322 (2012) 96–101.
D. Bellar, N.R. LeBlanc, B. Campbell, J. Int. Soc. Sports Nutr. 12 (2015) 42.